Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Tennessee Medical Center | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
It is well established that cancer cells have fundamentally altered metabolism, which contributes to tumorigenicity and malignancy. For years, research findings supported that the universal property of all cancer cells was to increase glycolytic flux for anaerobic glycolysis (i.e., Warburg effect), which was accepted as the dominant pathway for energy metabolism. Fortunately, by understanding these changes in cellular metabolism multiple new approaches to cancer therapy, focused on reprogramming the energy metabolism of the cell. Recently, further investigation in the field found that cancer cells exhibit multiple alterations in metabolic pathways, not only glycolysis.
Alterations in lipid metabolism in cancer cells have recently been recognized as potential targets for therapeutic interventions due to its role in cellular proliferation, energy storage, and the generation of signaling molecules. Numerous cancer types can rely on lipids as an energy source, increasing fatty acid synthesis and degradation to promote proliferation and metastasis. Several therapeutic agents utilized in gynecologic malignancies impact lipid metabolism.
The objective of the proposed study will be to determine the impact of cancer directed therapy on the lipid metabolism of non-malignant tissues. No study to date has assessed whole-body lipid metabolism in patients undergoing chemotherapy (i.e. cytotoxic chemotherapy and/or immunotherapy). These novel findings will provide crucial knowledge about the dysregulation of whole-body metabolism in patients receiving chemotherapy for treatment of gynecologic cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with biopsy proven gynecologic cancer | Patients with biopsy proven gynecologic cancer undergoing active treatment |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Fasting Whole Body Carbon Dioxide Production - Baseline | Fasting whole body carbon dioxide production (VCO2), which is assessed using indirect calorimetry and measured in ml/min. | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting Whole Body Oxygen Consumption - Baseline | Fasting whole body oxygen consumption (VO2), which is assessed using indirect calorimetry in ml/min | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting Resting Metabolic Rate (RMR) - Baseline | Fasting resting metabolic rate (RMR), which is assessed using indirect calorimetry and measured in kcal/day. | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting respiratory exchange ratio (RER) - Baseline | Fasting respiratory exchange ratio (RER), which is assessed using indirect calorimetry. | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting Whole Body Carbon Dioxide Production - 30 Minutes Post | Fasting whole body carbon dioxide production (VCO2), which is assessed using indirect calorimetry and measured in ml/min. | Fasting, measured 30 minutes after the start of a single cancer treatment during the study visit at one time point during active cancer treatment. |
| Fasting Whole Body Oxygen Consumption - 30 Minutes Post | Fasting whole body oxygen consumption (VO2), which is assessed using indirect calorimetry in ml/min |
| Measure | Description | Time Frame |
|---|---|---|
| Fasting capillary blood glucose | Fasting capillary blood glucose (mg/dL) | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting capillary blood lactate |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with gynecologic cancer engaged in active treatment.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | United States |
Datasets will not be publicly available but can be shared by request.
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010051 | Ovarian Neoplasms |
| D014594 | Uterine Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
venous blood
| Fasting, measured 30 minutes after the start of a single cancer treatment during the study visit at one time point during active cancer treatment. |
| Fasting Resting Metabolic Rate (RMR) - 30 Minutes Post | Fasting resting metabolic rate (RMR), which is assessed using indirect calorimetry and measured in kcal/day. | Fasting, measured 30 minutes after the start of a single cancer treatment during the study visit at one time point during active cancer treatment. |
| Fasting respiratory exchange ratio (RER) - 30 Minutes Post | Fasting respiratory exchange ratio (RER), which is assessed using indirect calorimetry. | Fasting, measured 30 minutes after the start of a single cancer treatment during the study visit at one time point during active cancer treatment. |
| Fasting Whole Body Carbon Dioxide Production - 90 Minutes Post | Fasting whole body carbon dioxide production (VCO2), which is assessed using indirect calorimetry and measured in ml/min. | Fasting, measured 90 minutes after the start of a single cancer treatment during the study visit at one time point during active cancer treatment. |
| Fasting Whole Body Oxygen Consumption - 90 Minutes Post | Fasting whole body oxygen consumption (VO2), which is assessed using indirect calorimetry in ml/min | Fasting, measured 90 minutes after the start of a single cancer treatment during the study visit at one time point during active cancer treatment. |
| Fasting Resting Metabolic Rate (RMR) - 90 Minutes Post | Fasting resting metabolic rate (RMR), which is assessed using indirect calorimetry and measured in kcal/day. | Fasting, measured 90 minutes after the start of a single cancer treatment during the study visit at one time point during active cancer treatment. |
| Fasting respiratory exchange ratio (RER) - 90 Minutes Post | Fasting respiratory exchange ratio (RER), which is assessed using indirect calorimetry. | Fasting, measured 90 minutes after the start of a single cancer treatment during the study visit at one time point during active cancer treatment. |
| Fasting Whole Body Carbon Dioxide Production - 150 Minutes Post | Fasting whole body carbon dioxide production (VCO2), which is assessed using indirect calorimetry and measured in ml/min. | Fasting, measured 150 minutes after the start of a single cancer treatment during the study visit at one time point during active cancer treatment. |
| Fasting Whole Body Oxygen Consumption - 150 Minutes Post | Fasting whole body oxygen consumption (VO2), which is assessed using indirect calorimetry in ml/min | Fasting, measured 150 minutes after the start of a single cancer treatment during the study visit at one time point during active cancer treatment. |
| Fasting Resting Metabolic Rate (RMR) - 150 Minutes Post | Fasting resting metabolic rate (RMR), which is assessed using indirect calorimetry and measured in kcal/day. | Fasting, measured 150 minutes after the start of a single cancer treatment during the study visit at one time point during active cancer treatment. |
| Fasting respiratory exchange ratio (RER) - 150 Minutes Post | Fasting respiratory exchange ratio (RER), which is assessed using indirect calorimetry. | Fasting, measured 150 minutes after the start of a single cancer treatment during the study visit at one time point during active cancer treatment. |
Fasting capillary blood lactate (mmol/L)
| Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting venous blood glucose | Fasting venous plasma glucose (mg/dL) | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting venous blood insulin | Fasting venous serum insulin (µlU/mL) | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting venous blood lactate | Fasting venous plasma blood lactate (mmol/L) | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting venous cholesterol (mg/dL) | Fasting venous cholesterol (mg/dL) | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting venous HDL (mg/dL) | Fasting venous HDL (mg/dL) | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting venous LDL (mg/dL) | Fasting venous LDL (mg/dL) | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting venous VLDL (mg/dL) | Fasting venous VLDL (mg/dL) | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| Fasting venous triglycerides (mg/dL) | Fasting venous triglycerides (mg/dL) | Fasting, measured at the start of the study visit at one time point during active cancer treatment. |
| D000291 |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |
| D014591 | Uterine Diseases |